Diffuse large B-cell lymphoma: new targets and novel therapies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33820908/

Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell prod ...